MMP13 and pterygium: In contrast, the intensity of both protein bands was significantly reduced in the pterygium tissues treated with bevacizumab (MMP-3, 0.13-fold; MMP-13, 1.27-fold), as compared to pterygium tissue from untreated patients (Fig 5C).